Novonesis Approves €1 Billion Inaugural Buyback as 8% H1 Organic Growth Lifts 2026 Outlook

Novonesis raised its full-year organic sales growth outlook to 7–8% on August 19, 2026, after posting 8% organic growth and a 37.7% adjusted EBITDA margin for the first half of 2026. It paired the upgrade with an inaugural multi-year share buyback of €1 billion and an interim dividend of DKK 2.35 per share.

The Copenhagen-based biosolutions company, formed by the combination of Novozymes and Chr. Hansen, had previously guided to 5–7% organic sales growth for 2026, a range it reaffirmed as recently as May 5, 2026, when it reported first-quarter organic growth of 7%. The adjusted EBITDA margin is now expected at the higher end of the existing 37–38% range.

Half-year sales came in at €2,235.5 million, up 7% in euro terms despite a 4-percentage-point currency headwind, with adjusted EBITDA of €842.2 million against €783.4 million in the first half of 2025, according to the interim report. Pricing contributed close to 2 percentage points of the organic growth, and revenue synergies from the company’s integration program added a good 1 percentage point.

President and CEO Ester Baiget tied the upgrade to demand across both divisions and geographies.

“We continue to deliver strong results with positive momentum across all sales areas and in both developed and emerging markets, also driving strong profitability and cash flow,” Baiget said in the half-year announcement. “On this basis, we raise the full-year outlook.”

Enzymes for Ethanol and Detergents Carry the Second Quarter

The growth engine in the quarter sat in Planetary Health Biosolutions, the division housing Novonesis’ agriculture, bioenergy, and household-care businesses, which grew 9% organically in Q2 and 7% for the half on sales of €1,236.4 million. Household Care (detergent enzymes and microbes) grew 12% organically in the quarter, with the interim report pointing to penetration gains among local and regional detergent producers and particularly strong emerging-market demand.

Agriculture, Energy & Tech, the division’s largest sales area at €811.2 million for the half, grew 7% organically in Q2. Energy was the driver: the report describes double-digit growth in bioenergy enzymes, led by Latin America and Asia Pacific on expanded ethanol production capacity, with North America lifted by rising ethanol output and accelerating exports as global biofuel demand builds. The company also cited growing penetration of biodiesel solutions and customer ramp-up of second-generation biomass ethanol.

The farm side of the book told a different story. The Plant business declined, which the interim report attributes to weak US farm economics making growers more cautious in their spending. Animal delivered solid underlying performance, though the first half’s 6% organic growth in the sales area was flattered by an inventory build at a key Animal customer in the first quarter, an effect the company says will be neutral for the full year. The Feed Enzyme Alliance acquisition, completed in June 2025, added 6–7 percentage points of reported sales growth in the area.

Food & Health Biosolutions grew 9% organically for the half on sales of €999.1 million, with Food & Beverages up 11% on demand for high-protein dairy and clean-label solutions, while Human Health managed 4% against a softer North American probiotic supplements market.

What the Numbers Fund

• Net sales, H1 2026: €2,235.5 million (H1 2025: €2,096.1 million)
• Adjusted EBITDA: €842.2 million, a 37.7% margin, up 30 basis points year over year including currency headwind
• Adjusted net profit excluding PPA: €507.1 million, up 8%
• Free cash flow before acquisitions: €307.6 million, 14% of sales
• Net interest-bearing debt to EBITDA: 1.8x, down from 2.1x a year earlier
• Share buyback: €1 billion, starting in the second half of 2026 and running to the end of 2029
• Interim dividend: DKK 2.35 (€0.31) per share, payable August 27, 2026

The buyback is the company’s first. Most repurchased shares will be cancelled, with a smaller portion covering employee share-program obligations, the interim report states. Novo Holdings, the principal shareholder, has told the company it intends to sell into the program to hold its stake at roughly 25.5% of share capital after the cancellations.

Capex is running at 9.7% of sales for the half, up from 6.6% a year earlier, and is guided to 12–14% of sales for the full year, tied to production-capacity expansions under the company’s 2030 strategy launched in August 2025. On April 1, 2026, the company acquired Plumino Precision Fermentation and its production facility in Rayong, Thailand, for €41.3 million net of cash; the site, which can support production of human milk oligosaccharides for infant nutrition, is expected to be commercially operational in 2027. In March 2026, the company also issued €1.7 billion in senior unsecured notes across three tranches at fixed rates of 3.25% to 4.00%, refinancing debt from the Feed Enzyme Alliance deal.

The Yeast Bolt-On and the Rest of 2026

Nine days before the earnings release, on August 10, 2026, Novonesis signed an agreement to acquire the remaining 77% of MicroBioGen, the Australian yeast-strain developer in which it has held a 23% stake since 2013. MicroBioGen’s platform, a library of elite yeast genetics built over 20 years, underpins the Innova yeast series the two companies co-developed for bioethanol production, the same energy business now delivering double-digit growth. Terms were not disclosed; completion is subject to regulatory approvals including from Australia’s competition regulator, the ACCC. For readers tracking the wider synthetic-biology sector, Securities.io maintains a list of listed synthetic-biology companies, and has profiled the biofoundry model at Ginkgo Bioworks (DNA ): a contrasting, services-heavy approach to the industrial biology Novonesis runs at fermentation scale.

The raised outlook still embeds constraints the company states plainly: a close to 1-percentage-point negative effect from exiting certain countries, a minor second-half drag from reimbursing US tariffs to customers, and a currency assumption that reported euro sales will land about half a percentage point below organic growth. The margin guidance leans on the 37–38% range’s upper end despite a USD exposure that leaves a 5% move in the dollar worth €40–45 million of adjusted EBITDA, with 72% of 2026 currency exposure hedged at an average EUR/USD rate of 1.15.

The next checkpoint is dated: the nine-month interim report lands November 5, 2026, and the buyback’s first purchases are scheduled within the second half of the year.